2338-05-8

Basic information

• Product Name: FERRIC CITRATE
• Synonyms: Iron(III) citrate tribasic monohydrate,Ferric citrate monohydrate;IRON(lll) CITRATE, hydrate, tech-95;Ferric Citrate, Powder;Iron(Ⅲ) Citrate n-Hydrate;2,3-propanetricarboxylicacid,2-hydroxy-ironsalt;IRON (III) CITRATE, GREEN;IRON CITRATE;FERRIC CITRATE
• CAS NO: 2338-05-8
• Molecular Formula: C6H5FeO7
• Molecular Weight: 244.94
• EINECS: 219-045-4
• Product Categories: Organic-metal salt
• Mol File: 2338-05-8.mol

Chemical Properties

• Boiling Point: 309.6oC at 760mmHg
• Flash Point: 155.2oC
• Appearance: /
• Density: 1.906[at 20℃]
• Vapor Pressure: 5.73E-05mmHg at 25°C
• Water Solubility: Soluble in water
• Stability: Stable. Light sensitive.
• Merck: 13,4050
• CAS DataBase Reference: FERRIC CITRATE(CAS DataBase Reference)
• NIST Chemistry Reference: FERRIC CITRATE(2338-05-8)
• EPA Substance Registry System: FERRIC CITRATE(2338-05-8)

Safety Data

• WGK Germany: 3
• F: 8
• Hazardous Substances Data: 2338-05-8(Hazardous Substances Data)

Usage

Uses

Used in Medicine:
Ferric Citrate is used as a nutrient supplement for the treatment of iron deficiency anemia. It helps in increasing the iron levels in the body, which is essential for the production of hemoglobin and maintaining overall health.
Used in Infant Formula:
Ferric Citrate is used as an iron source in infant formula to ensure that infants receive adequate amounts of iron for their growth and development. Iron is crucial for various bodily functions, including oxygen transport and energy production.
Used in Blueprint Paper:
Ferric Citrate is used as a component in the production of blueprint paper, which is a type of paper used for creating architectural and engineering drawings. The chemical properties of ferric citrate make it suitable for this application, as it can help in the development of the blue lines on the paper.

Flammability and Explosibility

Notclassified

Safety Profile

When heated to decomposition it emits acrid smoke and irritating fumes.

InChI:InChI=1/C6H8O7.Fe.4H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;4*1H2/q;+3;;;;/p-3

Synthetic route

citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
Stage #1: citric acid With sodium hydroxide In water for 0.5h; Stage #2: With iron(III) chloride hexahydrate In water at 50 - 55℃; for 1h;	85%

iron(III) oxide + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
In water at 75 - 80℃; for 4h;	83.8%

sodium citrate (68-04-2) → ferric citrate (2338-05-8)

Conditions	Yield
With iron(III) chloride hexahydrate In water at 80 - 90℃; for 1h;	78%

ferric nitrate (7782-61-8) + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
In water for 4h; Product distribution / selectivity;	54%
for 4h; Product distribution / selectivity;

iron(III) chloride + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
In ethanol; water for 1h; Product distribution / selectivity;
Stage #1: iron(III) chloride With sodium carbonate In water at 20℃; for 1h; Large scale; Stage #2: In water at 40 - 60℃; Large scale; Stage #3: citric acid In water at 60 - 100℃; for 1h; Large scale;	15.88 kg

iron (III) hydroxide + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
at 80 - 90℃;
at 30 - 90℃; pH=0.8 - 1.5;

iron(III) sulfate + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
In water mixed molar ratio ligand/Fe(3+) of slightly more than 1;

iron(III) chloride hexahydrate + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
Stage #1: iron(III) chloride hexahydrate With sodium hydroxide In water at 25 - 30℃; Large scale; Stage #2: citric acid In water at 80 - 85℃; Large scale;	1.25 kg
Stage #1: iron(III) chloride hexahydrate With sodium carbonate In water at 25 - 30℃; for 1.5h; pH=8 - 8.5; Stage #2: citric acid In water at 25 - 120℃; Reagent/catalyst; Temperature; pH-value;
Stage #1: iron(III) chloride hexahydrate With sodium hydroxide In water at 0 - 10℃; for 4h; Stage #2: citric acid In water at 20 - 85℃; for 2.5h;

iron(II) carbonate (767234-62-8) + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
In water at 80℃;

iron(III)-acetylacetonate (14024-18-1) + citric acid (77-92-9) → ferric citrate (2338-05-8)

Conditions	Yield
In water at 65℃; for 1h;	1.32 g

hydrogen fluoride (7664-39-3) + water (7732-18-5) + piperazinium sulfate (4554-26-1) + ferric citrate (2338-05-8) → 2H2N(CH2)4NH2(2+)*2Fe(3+)*3Fe(2+)*12F(1-)*2SO4(2-)*2H2O=[H2N(CH2)4NH2]2[Fe5F12(SO4)2(H2O)2]

Conditions	Yield
In water; ethylene glycol High Pressure; at 180°C for 2 d at constant pressure in a bomb, Fe:HF:H2O:piperazine sulfate:ethylene glycol=1:8:50:4:50 molar ratio; elem. anal.;	50%

sulfuric acid (7664-93-9) + hydrogen fluoride (7664-39-3) + ferric citrate (2338-05-8) + sodium sulfate (7757-82-6) → sodium ferric(III) fluorosulfate

Conditions	Yield
In water; butan-1-ol at 150℃; for 120h;	45%

1,4-diaza-bicyclo[2.2.2]octane (280-57-9) + sulfuric acid (7664-93-9) + hydrogen fluoride (7664-39-3) + water (7732-18-5) + ferric citrate (2338-05-8) → HN(CH2)6NH(2+)*2Fe(2+)*Fe(3+)*6F(1-)*2SO4(2-)*H(1+)*H2O=[HN(CH2)6NH][Fe3F6(SO4)2]*H3O

Conditions	Yield
In water; butan-1-ol High Pressure; at 180°C for 2 d at constant pressure in a bomb, Fe:H2SO4:HF:H2O:DABCO:n-butanol=1:4:4:50:6:30 molar ratio; elem. anal.;	40%

sulfuric acid (7664-93-9) + hydrogen fluoride (7664-39-3) + water (7732-18-5) + ferric citrate (2338-05-8) + 1,5-diamino-3-azapentane (111-40-0) → 4NH3CH2CH2NH2CH2CH2NH3(3+)*9Fe(2+)*18F(1-)*6SO4(2-)*9H2O=(NH3CH2CH2NH2CH2CH2NH3)4(Fe9F18(SO4)6)*9H2O

Conditions	Yield
In ethanol; water High Pressure; mixt. iron(III) citrate, H2SO4, HF, diethylenetriamine, EtOH and water (pH 4) was stirred for 2 h and heated in PTFE-lined acid-digestion bomb at 180°C for 4 days; react. mixt. was cooled to room temp., ppt. was filtered and washed withwater and EtOH;	30%

2-ethyl-3-hydroxy-4-pyranone (4940-11-8) + ferric citrate (2338-05-8) → 2C6H5O7(3-)*3C7H7FeO3(2+)

Conditions	Yield
In ethanol; water for 0.25h;

mer-tris(3-hydroxy-2-methyl-4H-pyran-4-onato)iron(III) (115648-45-8, 181656-66-6, 33725-54-1) + ferric citrate (2338-05-8) + citric acid (77-92-9) → ferric monomaltol citrate

Conditions	Yield
In water Heating / reflux;

Maltol (118-71-8) + ferric citrate (2338-05-8) → Reaxys ID: 11390965

Conditions	Yield
With sodium hydroxide In water at 20℃; pH=11.6; Product distribution / selectivity;

ferric citrate (2338-05-8) → iron(III) oxide

Conditions	Yield
In water spray pyrolysis of an aq. ferric citrate soln. on a heated glass substrate;

ferric citrate (2338-05-8) → iron(III) oxide

Conditions	Yield
ferric citrate decomp. in air at 773 K;
In neat (no solvent, solid phase) decompose (air), at 723 K for 3 h; XRD;

strontium(II) carbonate (1633-05-2) + ferric citrate (2338-05-8) → strontium ferrite

Conditions	Yield
With citric acid In water byproducts: CO2; stoich. amt. of SrCO3 and ferric citrate dissolved in citric acid aq. soln. at 80°C; soln. slowly evapd.; residue heated at 200°C for 20 h; calcined at 1000°C for 1 h;

gadolinium(III) oxide + ferric citrate (2338-05-8) + citric acid (77-92-9) → gadolinium iron garnet

Conditions	Yield
In water excess citric acid; refluxed for 6 h; dried at 120°C; heated at 400°C for 24 h in 95%N2/5%O2, then 24 h at 400°C in air, then 1t 400 - 900°C for 4 h or heated in air for 24 h at 400°C, then for 4 h at 500-700°C;

bismuth(III) oxide (1304-76-3) + ferric citrate (2338-05-8) → bismuth ferrite

Conditions	Yield
With ethylene glycol; citric acid In nitric acid mixing of iron citrate soln. with soln. of Bi2O3 in dilute HNO3, addn. of soln. of citric acid and ethylene glycol, stirring at 70-80°C for 6 h, coating on SrTiO3 or LaAlO3 through fast spinning, drying, firing at 780°C in air for 1-12 h;

lanthanum(III) oxide + ferric citrate (2338-05-8) → lanthanum orthoferrite

Conditions	Yield
With citric acid; ethylene glycol In water; nitric acid La2O3, Fe citrate dissolved (HNO3); citric acid in H2O added; mixt. stirred at 60°C for 1 h; ethylene glycol added; stirred at 80°C; gel dried at 150°c for at least 20 h; heat treated at 400-600°C for 3 h; XRD;

barium citrate + ferric citrate (2338-05-8) → barium dodecairon nonadecoxide

Conditions	Yield
In water Fe citrate soln. was added to Ba citrate soln.; heated to dryness at 40°C; glassy brown citrate mixture was heated at temp. between 300 and 800°C; calcined at 600°C for 3 h; pressed into pellets; sintered (800 - 1300°C);
In water mixing of soln. of barium and iron(III) citrates in Ba(2+):Fe(3+)=1:12; ultrazonic spraying at 900°C; firing at 580°C;

manganese(II)carbonate + ferric citrate (2338-05-8) + zinc(II) oxide → MnO(16.6),ZnO(8.6),Fe2O3(74.8) (W%)

Conditions	Yield
With ammonium hydroxide; citric acid In water mixed soln. of educts (citric acid, deionized H2O, 14.8N NH4OH), sprayed by a ultrasonic probe into a 10fold vol. of EtOH, washed (EtOH), filtered, vac. dried at 40-50°C, calcined at 300°C(open vessel, air), 5h, at 900°C(closed), 4h;

manganese(II)carbonate + ferric citrate (2338-05-8) + zinc(II) oxide → MnO(25.2),ZnO(0.3),Fe2O3(74.5) (W%)

Conditions	Yield
With ammonium hydroxide; citric acid In water mixed soln. of educts (citric acid, deionized H2O, 4.8N NH4OH) sprayed by a ultrasonic probe into a 10fold vol. of EtOH, washed(EtOH), filtered, vac. dried at 40-50°C, calcined at 300°C (open vessel, air), 5h, at 900°C (closed), 4h;

manganese(II)carbonate + ferric citrate (2338-05-8) + zinc(II) oxide → MnO(14.1),ZnO(15.8),Fe2O3(70.1) (W%)

Conditions	Yield
With ammonium hydroxide; formic acid In formic acid; water mixed soln. of educts (formic acid, deionized H2O, 14.8N NH4OH) sprayed by a ultrasonic probe into a 10fold vol. of EtOH, washed(EtOH), filtered, vac. dried at 40-50°C, calcined at 300°C (open vessel, air), 5h, at 900°C (closed), 4h;

manganese(II)carbonate + ferric citrate (2338-05-8) + zinc(II) oxide → MnO(6.6),ZnO(23.7),Fe2O3(69.7) (W%)

Conditions	Yield
With ammonium hydroxide; citric acid In water mixed soln. of educts (citric acid, deionized H2O, 14.8N NH4OH) sprayed by a ultrasonic probe into a 10fold vol. of EtOH, washed(EtOH), filtered, vac. dried at 40-50°C, calcined at 300°C (open vessel, air), 5h, at 900°C (closed), 4h;

manganese(II)carbonate + ferric citrate (2338-05-8) + zinc(II) oxide → MnO(16.0),ZnO(15.5),Fe2O3(68.4) (W%)

Conditions	Yield
With ammonium hydroxide; formic acid In formic acid; water mixed soln. of educts (formic acid, deionized H2O, 14.8N NH4OH) sprayed by a ultrasonic probe into a 10fold vol. of EtOH, washed(EtOH), filtered, vac. dried at 40-50°C, calcined at 300°C(open vessel, air), 5h, at 900°C (closed), 4h;

cobalt(II) acetate (71-48-7, 917-69-1, 5931-89-5, 55881-15-7, 68931-68-0, 68931-69-1, 93029-27-7) + barium(II) acetate (543-80-6) + ferric citrate (2338-05-8) + citric acid (77-92-9) → Z-hexaferrite

Conditions	Yield
With aq. ammonia; air In water sol-gel method; Fe salt dissolved in aq. citric acid at 70°C; mixed with stoich. amt. of Ba and Co acetates; NH3 soln. added (pH 6-8); sol dried at 135°C for 6 h; decompd. (600°C, 4 h); heat treated at 1200°C for 6 h in air; satisfactory elem. anal.;

manganese(II) citrate (5968-88-7, 10024-66-5, 10060-26-1, 65128-61-2, 71799-92-3, 85514-17-6) + ferric citrate (2338-05-8) → manganese ferrite

Conditions	Yield
In water aq. soln. of manganese citrate and ferric citrate (Fe:Mn=2:1) mixed, pH=3, heated under reflux at 363 K for 10 h, evapd., citrate precursor decompd. in N2 atmosphere at different time duration and temp.;

nickel citrate + ferric citrate (2338-05-8) → nickel(II) ferrite

Conditions	Yield
In neat (no solvent) sintered at 1100°C for 2 h;

lead(II) nitrate + ferric citrate (2338-05-8) + citric acid (77-92-9) → lead ferrite

Conditions	Yield
In neat (no solvent) lead citrate formed from lead nitrate and citric acid, mixed with ferriccitrate, pH of soln. 2.6, refluxed at 100 °C 12 h, dehydrated fr om ethanol (1:10 ratio) to obtain the citrate precursor; thermal decompn. in air between 773-1073 K; chemical analysis;

Upstream product

• 7782-61-8 ferric nitrate 
• 77-92-9 citric acid 
• 14024-18-1 iron(III)-acetylacetonate 
• 68-04-2 sodium citrate 
• 767234-62-8 iron(II) carbonate 

Relevant articles and documents

MCC: Specific of preparation, correlation of the phase composition and electrodynamic properties

Metal-carbon composites (MCC) were produced by the dissolving of the Fe, Co and Ce nitrates in phenol–formaldehyde resin with further pyrolysis (under heating up to 800 °C). Concentrations of the metal compositions in final MCC were 2, 7 and 15 wt%. Phase

PROCESS FOR THE PREPARATION OF FERRIC ORGANIC COMPOUNDS

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described.

Manufacturing Method of Ferric Citrate

A method of manufacturing is provided for obtaining ferric citrate by a simple drying operation, the ferric citrate having a high purity, a high specific surface area, and a reduced water-soluble organic solvent content. The method of manufacturing ferric citrate, comprises a wet material of ferric citrate, containing the ferric citrate and a water-soluble organic solvent and having a water-soluble organic solvent content within the range of more than 0.3% by mass to 30.0% by mass or less, dried by bringing a gas containing water into contact.

Preparation method of medicinal grade ferric citrate

The invention discloses a preparation method of medicinal grade ferric citrate. The method comprises the following steps that citric acid and iron oxide are dissolved in water for a reaction, whereinthe molar ratio of the citric acid to the iron oxide to the water is (1.1-3):1:(40-80), the reaction temperature is 75-80 DEG C, and the reaction time is 1-12 hours; the mixture above is cooled to theroom temperature, and an organic solvent is added dropwise, wherein the molar ratio of the organic solvent to the iron oxide is (35-125): 1; after dropwise addition of the organic solvent is completed, stirring is carried out for a reaction for 0.1-10 hours, filtering is carried out, a filter cake is washed with an organic solvent, and drying under reduced pressure is carried out at 40-50 DEG C for 1-12 hours to obtain the medicinal grade ferric citrate. According to the provided preparation method of the medicinal grade ferric citrate, the iron oxide is used for replacing ferric chloride, noinorganic salt is formed during the reaction, the operation is simple, and the prepared ferric citrate has uniform components and contains 2.5 water crystals, the specific surface area is 32.4-39.9 m/g, and medicinal grade requirements are met.

Method for the Synthesis of Ferric Oraganic Compounds

The present invention relates to an improved method for the synthesis of Ferric Citrate and also to provide an amorphous form of Ferric Citrate having an active surface area less than 14 sq.m/g.

PROCESS FOR THE PREPARATION OF PHARMACEUTICAL GRADE FERRIC CITRATE

The objective of the present invention is a one-pot process for the preparation of pharmaceutical grade ferric citrate comprises of preparing a ferric hydroxide slurry followed by treatment with a citrate ion source to yield pharmaceutical grade ferric citrate.

PROCESS FOR PREPARING PHARMACEUTICAL GRADE FERRIC CITRATE

The invention relates to a method for preparing pharmaceutical grade ferric citrate that has a BET active surface area of 2/g and a dissolution rate of 4 to 9 mg/cm2/min. The invention further provides pharmaceutical grade ferric citrate that is characterized by a BET active surface area of 2/g and a dissolution rate of 4 to 9 mg/cm2/min.

PHARMACEUTICAL GRADE FERRIC CITRATE AND METHOD FOR ITS PRODUCTION

Ferric citrate is provided having a BET active surface area in the range of 1-15 m2 /gm. A method for preparing pharmaceutical grade ferric citrate is also provided.

TABLET CONTAINING FERRIC CITRATE

The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.

METHOD OF TREATING CHRONIC KIDNEY DISEASE

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.